The dual shelf effectiveness removes a procedural barrier to raising capital. With weak analyst sentiment and minimal institutional support, the risk of a dilutive offering is elevated. Traders should watch for a prospectus supplement or 424B filing that would signal an actual offering, that event would likely pressure the stock.
ESPR drugs
ESPR drug pipeline →Price Chart
How similar events traded
Executive Summary
Esperion Therapeutics received SEC effectiveness on two shelf registration statements (File Nos. 333-201198 and 333-197125) on July 15, 2026. Both are now effective, giving the company the ability to offer and sell securities at any time. This creates a potential dilution overhang for common shareholders, as the company can tap the market without further notice.
Key Facts
- Two shelf registration statements (333-201198 and 333-197125) declared effective by the SEC on July 15, 2026.
- Both are 1933 Act filings, enabling Esperion to offer and sell securities (common stock, preferred stock, warrants, etc.) at its discretion.
- No specific offering size, pricing, or terms were disclosed in the effectiveness notices.
- The company has a market cap of approximately $819M and is covered by 0 Strong Buy ratings (0% bullish analyst consensus).
- Top institutional holder Wasatch Advisors holds only $6M, and recent 13F activity shows a near-exit move.
Financial Impact
Potential dilution of unknown size, shelf registrations allow for offerings up to undisclosed amounts. Any future offering could dilute existing common shareholders.
Risk Factors
- Potential dilutive equity offering at any time without prior notice.
- Weak analyst consensus (0% bullish) and low institutional conviction (Wasatch near-exit) suggest limited demand for the stock.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (ESPR), Batch item 1 | 9999999995-26-002302 |
| Document: 9999999995-26-002302-index.html | 9999999995-26-002301 |
| Document: 9999999995-26-002302.txt | 9999999995-26-002302 |
| EFFECT Filing (ESPR), Batch item 4 | 9999999995-26-002301 |
| Document: 9999999995-26-002301-index.html | 9999999995-26-002302 |
| Document: 9999999995-26-002301.txt | 9999999995-26-002302 |
Track record
21 reports on ESPR
4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +16.30% at T+60 after the Mar 10, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G/A Bearish 4/10 No price data
- Sep 3, 202610w ago Court Ruling Bullish 5/10 No price data
- Aug 13, 202613w ago Institutional Cluster Bearish 5/10 No price data
- Jul 23, 202616w ago 15-12G Neutral 5/10 No price data
- Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
- Jul 16, 202617w ago EFFECT Bearish 5/10 Viewing Entry $3.18 No price data
- Jul 13, 202618w ago 25-NSE Bullish 7/10 Entry $3.19 No price data
- Jul 13, 202618w ago 8-K Bullish 7/10 Entry $3.19 No price data
- Jun 16, 202621w ago DEFA14A Bullish 6/10 Entry $3.17 No price data
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.15 to $3.19 ▲ +1.27% −0.62% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers